Scarica l'app Stockscreener
12.76
1.27%
0.16
Dopo l'orario di chiusura:
12.70
-0.06
-0.47%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Viatris Inc Borsa (VTRS) Ultime notizie
Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target - Yahoo Finance
Viatris Inc.: Can a Hybrid Pharma Powerhouse Reinvent the Generic Drug Game? - AD HOC NEWS
Can Viatris Inc. stock deliver strong Q4 earningsTrend Reversal & Growth Focused Entry Point Reports - ulpravda.ru
How analysts revise price targets for Viatris Inc. (VIA) stockCPI Data & High Conviction Investment Ideas - ulpravda.ru
Does Viatris Inc. (VIA) stock trade below intrinsic value2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru
Performance Recap: Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru
Viatris names veteran executive to lead people and corporate affairs - The Business Journals
Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa
Why Viatris Inc. stock remains on buy listsEarnings Trend Report & AI Powered Trade Plan Recommendations - ulpravda.ru
Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - MarketScreener
Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia
Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris
Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS
Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves - MSN
Is Viatris stock outperforming the Dow? - MSN
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Taxanes Market to Reach US$ 8.67 Billion by 2032 at 10.73% CAGR; - openPR.com
1 Healthcare Stock to Target This Week and 2 We Turn Down - FinancialContent
A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones - Yahoo Finance
Anti-Depression Drugs Market to Reach USD 22.10 Billion by 2031 | - openPR.com
Viatris Inc.: Can a Hybrid Pharma Powerhouse Redefine Global Generics and Biosimilars? - AD HOC NEWS
Take Profit: Will Viatris Inc stock outperform Nasdaq indexJuly 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn
Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones - Finviz
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris stock hits 52-week high at $12.60 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $12.60 - Investing.com India
Viatris Inc. stock rises Wednesday, outperforms market - MSN
Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves - Insider Monkey
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Navigating a 3.90% Dividend Yield Amidst Challenging Metrics - DirectorsTalk Interviews
Viatris Inc. Stock Climbs 1.8%, Outperforms Market - 富途牛牛
Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025 - FinancialContent
How Is The Market Feeling About Viatris Inc?Viatris (NASDAQ:VTRS) - Benzinga
Viatris: Looks Cheap, But Faces Continued Contraction (NASDAQ:VTRS) - Seeking Alpha
Wall Street Recap: How strong is Viatris Inc. stock revenue growthStock Surge & Safe Capital Growth Trade Ideas - moha.gov.vn
Earnings Risk: How Viatris Inc. (VIA) stock trades after earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS? - Yahoo Finance
Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment - Yahoo Finance
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates - Yahoo News Malaysia
Is Viatris Inc. stock safe for conservative investorsEarnings Miss & Fast Moving Stock Watchlists - DonanımHaber
Viatris’ MR-146 gains IND clearance for neurotrophic keratopathy - BioWorld MedTech
Viatris secures four regulatory milestones across global pipeline By Investing.com - Investing.com Australia
Will Viatris Inc. stock outperform Nasdaq index2025 Valuation Update & Verified Technical Trade Signals - DonanımHaber
Viatris Provides Pipeline Update on Four Regulatory Milestones - The Malaysian Reserve
Update Recap: How Viatris Inc. stock valuations compare to rivalsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com
Viatris racks up regulatory wins across therapy areas - The Pharma Letter
0.16%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):